Caraco's Meloxicam tablets for osteoarthritis receive FDA approval

By Lisa Kerner

Charlotte, N.C., July 19 - Caraco Pharmaceutical Laboratories, Ltd. received approval from the Food and Drug Administration for its Abbreviated New Drug Application for Meloxicam tablets, the generic equivalent of Boehringer Ingelheim's Mobic.

Caraco has two strengths available (7.5 mg and 15 mg tablets) of the nonsteroidal anti-inflammatory drug for the relief of the signs and symptoms of osteoarthritis.

"We plan to launch this product to the market immediately," chief executive officer Daniel H. Movens said in a company news release.

"This approval brings our total marketed product selection to 22 different products represented by 47 strengths."

Detroit-based Caraco develops, manufactures and distributes generic and private-label prescription pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.